Cancer Stem Cell News Volume 11.32 | Sep 7 2022


    2022-09-08 | CSCN 11.32

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.32 – 7 September, 2022

    p53 Inhibits BMI-1-Driven Self-Renewal and Defines Salivary Gland Cancer Stemness

    Using gene silencing and therapeutic activation of p53, researchers analyzed the cell cycle profiles and apoptosis levels of CSCs in mucoepidermoid carcinoma cell lines via flow cytometry and looked at the effects on survival/self-renewal of the CSCs through sphere assays.
    [Clinical Cancer Research]

    PUBLICATIONSRanked by the impact factor of the journal

    Miat and Interacting Protein Metadherin Maintain a Stem-Like Niche to Promote Medulloblastoma Tumorigenesis and Treatment Resistance

    Investigators identified Miat as an lncRNA enriched in the sonic hedgehog group of medulloblastoma that was required for maintenance of a treatment-resistant stem-like phenotype in the disease.
    [Proceedings of the National Academy of Sciences of the United States of America]


    3D Matrix Promotes Cell Dedifferentiation into Colorectal Cancer Stem Cells via Integrin/Cytoskeleton/Glycolysis Signaling

    The 3D extracellular matrix could mediate cytoskeletal F-actin bundling through biomechanical force associated receptors integrin β1, contributing to the release of E3 ligase Tripartite motif protein 11 from cytoskeleton and degradation of the glycolytic rate-limiting enzyme phosphofructokinase.
    [Cancer Science]


    Leukocyte Cell-Derived Chemotaxin 2 Regulates Epithelial-Mesenchymal Transition and Cancer Stemness in Hepatocellular Carcinoma

    Scientists showed that exogenous leukocyte cell-derived chemotaxin 2 treatment inhibited CSC functions such as tumor sphere formation and drug efflux.
    [Journal of Biological Chemistry]

    Full Article

    PDE4 Inhibitor Eliminates Breast Cancer Stem Cells via Noncanonical Activation of mTOR

    The effects of rolipram, a PDE4 inhibitor, were evaluated on PI3K regulators and signaling. The efficacy of rolipram was compared with paclitaxel, an anticancer drug that was ineffective in obliterating breast CSCs.
    [Journal of Cellular Biochemistry]


    Cancer Associated Fibroblasts Secreted Exosomal miR-1290 Contributes to Prostate Cancer Cell Growth and Metastasis via Targeting GSK3β

    Investigators discovered that cancer-associated fibroblasts-exosomes remarkably enhanced prostate cancer cell migration, invasion, stemness, epithelial-mesenchymal transition, and metastasis.
    [Cell Death Discovery]

    Full Article

    RNF126 Contributes to Stem Cell-Like Properties and Metastasis in Hepatocellular Carcinoma through Ubiquitination and Degradation of LKB1

    By analyzing a database and verifying with their clinical specimens, scientists found that RNF126 was highly expressed in hepatocellular carcinoma tissues, which was associated with shorter overall survival and higher recurrence rate.
    [Human Cell]


    GANT61 Exerts Anticancer Cell and Anticancer Stem Cell Capacity in Colorectal Cancer by Blocking the Wnt/β-Catenin and Notch Signaling Pathways

    The authors assessed the anti-cancer cell and anti-CSC effects of GANT61, and its regulatory influence on the Wnt/β‑catenin and Notch signaling pathways in colorectal cancer.
    [Oncology Reports]


    The Role of LINC01419 in Regulating the Cell Stemness in Lung Adenocarcinoma through Recruiting EZH2 and Regulating FBP1 Expression

    In lung adenocarcinoma cells, proliferation and stem cell sphere-formation that were attenuated by LINC01419 knockdown were discovered to be facilitated by LINC01419 overexpression.
    [Biology Direct]

    Full Article
    Enjoy your weekend. Your cells will too. Reduce medium acidosis with mTeSR™ Plus.

    Tumor-Associated Macrophages in Liver Cancer: From Mechanisms to Therapy

    Complex crosstalk occurs between tumor-associated macrophages (TAMs) and liver cancer cells. TAMs play indispensable roles in tumor progression, angiogenesis, and autophagy due to their heterogeneity and robust plasticity.
    [Cancer Communications]

    Full Article


    Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

    Immutep Limited announced it has signed a Material Transfer Agreement with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland to enable an investigator-initiated open label Phase II clinical trial.
    [Immutep Limited]

    Press Release

    Two McGill Researchers Are Awarded through the TRANSCAN International Grant Competition

    The results of the Next Generation Cancer Immunotherapy: Targeting the Tumor Microenvironment funding call are out. 20 consortia were selected for funding with a total amount of €25.9 million. Two of these were Rosalind and Morris Goodman Cancer Institute researchers, Professors Daniela Quail and Morag Park.
    [McGill Reporter]



    Cell Bio 2022

    December 3-7, 2022
    Washington, DC, United States

    > See All Events


    Associate Researcher – Translational Cancer Research

    Icahn School of Medicine at Mount Sinai – New York City, New York, United States

    Postdoctoral Fellow – Breast Cancer Research

    Gunderson Health System – La Crosse, Wisconsin, United States

    Research Assistant Professor – Pancreatic Cancer Metabolism

    The University of Oklahoma – Oklahoma City, Oklahoma, United States

    Postdoctoral Scholar – Oncology

    University of California San Francisco – San Francisco, California, United States

    PhD Position – Tumor Heterogeneity

    German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter